SHR-A1811: Clinical Trials

10 trials of SHR-A1811, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

4 active not recruiting, 3 not yet recruiting, 3 recruiting. 10 Phase 3.

By phase and status

PhaseTrialsStatus
Phase 310Active not recruiting 4, Not yet recruiting 3, Recruiting 3

Follow SHR-A1811: new trials by email Literature Review of SHR-A1811 trials Research Report on SHR-A1811

Trials (filtered) newest first · largest first

All 10 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
A Study of HER2-Targeted Antibody-Drug Conjugates Compared With Hormone-Based Therapy for Hormone Receptor-Positive, HER2-Low Metastatic Breast Cancer
Trastuzumab Deruxtecan, SHR-A1811, Hormone Receptor-Directed Therapy - Metastatic Breast Cancer, Hormone Receptor-Positive Breast Cancer
Phase 3Not yet recruitingSun Yat-Sen Memorial Hospital of Sun Yat-Sen University2882026-11-012026-11-20
Famitinib Combined With SHR-A1811, Versus SHR-A1811 for CDK4/6 Inhibitors-resistent Advanced HR+/HER2- Breast Cancer With SNF4 Subtype
SHR-A1811, Famitinib+SHR-A1811 - Breast Cancer
Phase 3Not yet recruitingFudan University2482026-02-262026-02-03
SHR - A1811 Versus Chemotherapy for Platinum-resistant Recurrent Epithelial Ovarian Cancer
SHR-A1811, Chemotherapy - Ovarian Cancer
Phase 3Not yet recruitingTongji Hospital3002025-06-012025-05-25
A Study of SHR-A1811 in Subjects With Ovarian Cancer
SHR-A1811, Paclitaxel Injection, Doxorubicin Hydrochloride Liposome Injection - Ovarian Cancer
Phase 3RecruitingJiangsu HengRui Medicine Co., Ltd.3002025-03-132026-04-20
A Study of SHR-A1811 in First-line Treatment of Patients With Advanced or Metastatic Non-small Cell Lung Cancer With HER2 Mutations
SHR-A1811, PD-1/PD-L1 inhibitors、Pemetrexed/ Paclitaxel、Carboplatin/ Cisplatin - Non-Small Cell Lung Cancer With HER2- Mutations
Phase 3RecruitingJiangsu HengRui Medicine Co., Ltd.3002024-07-292026-01-21
Injection of SHR-A1811 Versus Physician Choiced Treatment in Patients With Advanced Colorectal Cancer Who Had Failed to Respond to Oxaliplatin, 5-fu, and Irinotecan
SHR-A1811, TAS-102, Regorafenib , Fruquintinib - Advanced Colorectal Cancer
Phase 3Active not recruitingSuzhou Suncadia Biopharmaceuticals Co., Ltd.1302024-03-012025-07-17
SHR-A1811 for Subjects With Her2-positive Gastric Cancer and Gastroesophageal Junction Adenocarcinoma After Progression on or After First-line Anti-HER2 Therapy-containing Regimen
SHR-A1811, Ramucirumab / Paclitaxel/ Docetaxel/ Irinotecan - HER2-positive Advanced Gastric Cancer or Gastroesophageal Junction Adenocarcinoma
Phase 3RecruitingJiangsu HengRui Medicine Co., Ltd.3602024-01-092024-01-16
A Phase III, Active-Controlled Study of SHR-A1811 Versus Trastuzumab Emtansine (T-DM1) in HER2-Positive Primary Breast Cancer Participants With Residual Invasive Disease Following Neoadjuvant Therapy
SHR-A1811, Trastuzumab Emtansine - HER2-Positive Primary Breast Cancer Participants With Residual Invasive Disease Following Neoadjuvant Therapy
Phase 3Active not recruitingJiangsu HengRui Medicine Co., Ltd.16152023-11-202026-06-30
SHR-A1811 Versus Investigator's Chemotherapy in Recurrent/Metastatic Breast Cancer Clinical Trial
SHR-A1811, Capecitabine/Eribulin/Gemcitabine/Paclitaxel/Nab-paclitaxel - Breast Cancer
Phase 3Active not recruitingJiangsu HengRui Medicine Co., Ltd.5512023-06-302026-08-06
A Trial of SHR-A1811versus Pyrotinib in Combination With Capecitabine in HER2-Positive, Unresectable and/or Metastatic Breast Cancer Subjects Previously Treated With Trastuzumab and Taxane
SHR-A1811, Pyrotinib in combination with Capecitabine. - HER2-Positive, Unresectable and/or Metastatic Breast Cancer Subjects Previously Treated With Trastuzumab and Taxane
Phase 3Active not recruitingJiangsu HengRui Medicine Co., Ltd.3812022-08-042025-08-22

Conditions studied

Breast Neoplasms (3)  ·  Ovarian Neoplasms (2)

Sponsors

Jiangsu HengRui Medicine Co., Ltd. (6)  ·  Fudan University (1)  ·  Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University (1)  ·  Suzhou Suncadia Biopharmaceuticals Co., Ltd. (1)  ·  Tongji Hospital (1)

Countries

China (10)

Top investigators

Qinglei Gao (1)

Results publications

PMID 42385760